⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Consult your healthcare provider before starting any medication.
"Insulin resistance" is one of the most commonly used — and least understood — phrases in metabolic health. If you have type 2 diabetes, prediabetes, PCOS, non-alcoholic fatty liver disease (NAFLD), or you are using a GLP-1 medication like Ozempic (semaglutide) or Mounjaro (tirzepatide), your doctor has almost certainly mentioned insulin resistance. But what does it actually mean? How do you test for it? What do the numbers mean for an Indian patient specifically? And how do GLP-1 medications address it?
This guide answers all of those questions in plain language.
Insulin is a hormone produced by the pancreas. Its primary job is to act as a "key" that unlocks cells — particularly muscle, liver, and fat cells — so glucose from the bloodstream can enter those cells and be used for energy.
Insulin resistance occurs when cells stop responding efficiently to insulin's signal. The lock on the cell door has changed. The same amount of insulin that previously opened the door easily now works poorly. The pancreas responds by producing more insulin — trying to compensate with quantity what it has lost in efficiency.
This compensated state can persist for years — even decades — without causing obvious symptoms. Blood glucose remains relatively normal because the pancreas is working overtime. But this overwork gradually exhausts the insulin-producing beta cells. When the pancreas can no longer produce enough extra insulin to maintain normal blood glucose, glucose rises: first to prediabetic levels (impaired fasting glucose or impaired glucose tolerance), then to frank type 2 diabetes.
Key insight: By the time a person is diagnosed with type 2 diabetes, they have often had insulin resistance for 10–15 years without knowing it.
Indian people — and South Asians broadly — have a disproportionately high rate of insulin resistance compared to European populations, even at lower body weights and BMIs. This is one of the defining public health challenges for India in the 21st century.
Body fat distribution: Indians tend to accumulate significantly more visceral fat (deep abdominal and organ fat) relative to total body weight compared to European populations. Visceral fat is metabolically dangerous — it secretes inflammatory adipokines (leptin, TNF-α, IL-6, resistin) that directly impair insulin signalling in muscle and liver cells. An Indian person with a BMI of 24 may have as much visceral fat — and as much insulin resistance — as a European person with a BMI of 30.
Genetic predisposition: Certain genetic variants associated with impaired beta cell function and altered insulin signalling (including variants in TCF7L2, PPARG, and KCNJ11) are more prevalent in South Asian populations, lowering the threshold at which insulin resistance translates to beta cell failure.
The thin-fat Indian phenotype: Normal or low BMI combined with high body fat percentage and visceral fat — sometimes called TOFI (Thin Outside, Fat Inside) — is common in India. An Indian person with a BMI of 22 and normal blood glucose can already have HOMA-IR values above 3.0. Standard global BMI thresholds were developed in European populations and significantly underestimate metabolic risk in South Asians.
The WHO now recommends separate BMI thresholds for Asians:
A 2023 study in The Lancet Diabetes & Endocrinology estimated 136 million Indians currently have diabetes — the highest number in any country globally — with an equal or greater number living with prediabetes and undiagnosed insulin resistance.
The simplest starting point. A morning fasting glucose ≥ 100 mg/dL indicates impaired fasting glucose — a direct marker of insulin resistance.
| Result | Interpretation |
|---|---|
| < 100 mg/dL | Normal |
| 100–125 mg/dL | Impaired fasting glucose / prediabetes |
| ≥ 126 mg/dL (×2) | Diabetes |
Indian context: Available at any pathology laboratory for ₹50–150. No prescription required. Test after 8–10 hours of fasting.
Reflects average blood glucose over the past 2–3 months. More reliable than a single fasting glucose.
| HbA1c | Interpretation |
|---|---|
| < 5.7% | Normal |
| 5.7–6.4% | Prediabetes |
| ≥ 6.5% | Diabetes |
Indian context: ₹300–800 at major diagnostic chains (Dr Lal PathLabs, SRL, Thyrocare).
This is the most informative but least commonly ordered test. A normal fasting glucose with an elevated fasting insulin directly reveals insulin resistance — the pancreas is working harder than normal to maintain that "normal" glucose level.
| Fasting Insulin | Interpretation |
|---|---|
| 2–5 µIU/mL | Optimal — insulin sensitive |
| 6–9 µIU/mL | Mild resistance |
| 10–25 µIU/mL | Significant resistance |
| > 25 µIU/mL | Severe resistance |
Indian context: Available at larger diagnostic labs (₹500–1,000). Ask specifically for "fasting serum insulin." Not offered by all smaller labs — request it from your doctor by name.
Calculated from fasting glucose and fasting insulin together. HOMA-IR gives a single number representing your insulin resistance level.
Formula: HOMA-IR = [Fasting Glucose (mg/dL) × Fasting Insulin (µIU/mL)] ÷ 405
Interpretation:
| HOMA-IR | Interpretation |
|---|---|
| ≤ 1.5 | Insulin sensitive (ideal) |
| 1.5–2.5 | Mild insulin resistance |
| 2.5–5.0 | Moderate insulin resistance |
| > 5.0 | Severe insulin resistance |
Example calculation: Fasting glucose 108 mg/dL, fasting insulin 18 µIU/mL → HOMA-IR = (108 × 18) ÷ 405 = 4.8 → Moderate-to-severe insulin resistance.
You can calculate this yourself once you have both test results. No special equipment needed.
High triglycerides combined with low HDL is a strong and easily obtained proxy for insulin resistance, derivable from any standard lipid profile.
Formula: Triglycerides (mg/dL) ÷ HDL (mg/dL)
| Ratio | Interpretation |
|---|---|
| < 3.5 | Low insulin resistance |
| 3.5–5.0 | Moderate — investigate further |
| > 5.0 | High insulin resistance |
Indian context: A standard lipid profile (₹400–700) provides all the numbers needed. Many Indians with insulin resistance have elevated triglycerides (> 150 mg/dL) and low HDL (< 40 mg/dL in men, < 50 mg/dL in women).
This is the most important and actionable stage. Your pancreas is still compensating. Research from the Diabetes Prevention Program (NEJM 2002) showed that lifestyle interventions reducing body weight by 7% prevented or significantly delayed type 2 diabetes in 58% of prediabetic participants.
GLP-1 medications at the prediabetic stage may be prescribed in India for:
Insulin resistance is the underlying cause, but beta cell dysfunction is also present. GLP-1 medications work on both simultaneously — improving insulin sensitivity while providing glucose-dependent insulin secretion support.
Even without diabetes, GLP-1 medications improve insulin sensitivity as a direct pharmacological effect — independent of and in addition to the improvement driven by weight loss. Many patients see improvements in their HOMA-IR within 4–8 weeks of starting, before significant weight change occurs.
GLP-1 receptor agonists (semaglutide, tirzepatide) address insulin resistance through four distinct mechanisms:
1. Weight loss, particularly visceral fat reduction
Every 1 kg of total weight lost reduces insulin resistance meaningfully. But more importantly, GLP-1 medications produce disproportionate visceral fat reduction relative to total fat loss — directly attacking the primary driver of insulin resistance in Indian patients. SURPASS-CVOT data showed tirzepatide reduced visceral adipose tissue volume by 17% after 52 weeks — a larger reduction than seen with other anti-obesity medications.
2. Glucose-dependent insulin secretion
GLP-1 medications stimulate insulin release only when blood glucose is elevated. This smart, contextual insulin stimulation does not cause the beta cell exhaustion associated with sulphonylureas, which push the pancreas to secrete insulin regardless of glucose level.
3. Reduced hepatic glucose production
GLP-1 receptors are expressed in the liver. Activation suppresses the liver's tendency to dump glucose into the bloodstream overnight and between meals — a major driver of elevated fasting glucose in insulin-resistant patients. This explains why many patients see their fasting glucose improve within weeks of starting a GLP-1 medication.
4. Direct tissue insulin sensitisation
Tirzepatide (Mounjaro) additionally activates GIP receptors expressed in adipose tissue, which modulates fat storage and release in ways that directly improve peripheral insulin sensitivity — a mechanism beyond what pure GLP-1 agonists provide.
A fasting glucose of 95 mg/dL looks reassuringly normal. But if your fasting insulin is 22 µIU/mL, HOMA-IR is 5.2 — severe insulin resistance — and your pancreas is working overtime to maintain that "normal" glucose. The glucose number alone misses the underlying problem entirely. Always pair fasting insulin with fasting glucose.
Insulin resistance reversal is substantially easier at the prediabetic stage. By the time type 2 diabetes is diagnosed, up to 50% of pancreatic beta cell function may already be irreversibly lost. Most Indians are only tested for glucose and HbA1c — fasting insulin and HOMA-IR are rarely checked at routine health screenings. Ask your doctor to include these tests.
GLP-1 medications are the most powerful pharmacological tool available for improving insulin resistance, but they work synergistically with:
For Indian patients, waist circumference is as important as BMI. Indian-specific thresholds:
Many Indians with normal BMI but waist circumference above these thresholds have clinically significant insulin resistance. Measure your waist at the level of your navel, after exhaling normally.
Request a fasting insulin level and HOMA-IR calculation if you have:
Q: Is insulin resistance the same as diabetes?
No. Insulin resistance is the upstream metabolic problem; diabetes is what happens downstream after years of unaddressed insulin resistance cause the pancreas to fail. Many people with significant insulin resistance have completely normal blood glucose — because their pancreas compensates. Treating insulin resistance at this compensated stage prevents diabetes from developing.
Q: Can insulin resistance be fully reversed?
In prediabetes, yes — with meaningful weight loss (7–10% of body weight), consistent resistance training, and dietary improvement, HOMA-IR can normalise in many patients. GLP-1 medications are currently the most effective pharmacological tool to achieve the weight loss necessary for this reversal. The SUSTAIN and SURPASS trials demonstrated normalisation of fasting insulin and HOMA-IR in a significant proportion of participants.
Q: I take metformin. Does insulin resistance still matter?
Yes. Metformin primarily reduces hepatic glucose production (liver glucose dumping) — it has limited effect on peripheral insulin resistance in muscle tissue. If you still experience weight gain, energy crashes, or your HOMA-IR remains elevated on metformin, peripheral insulin resistance is not adequately controlled. GLP-1 medications complement metformin's mechanism and address what metformin does not.
Q: How quickly do GLP-1 medications improve insulin resistance?
Measurable improvements in fasting insulin and HOMA-IR typically occur within 4–8 weeks of reaching therapeutic doses of semaglutide (0.5mg weekly) or tirzepatide (5mg weekly). This early improvement is largely independent of weight loss — it reflects direct pharmacological effects on hepatic glucose production and pancreatic function. Improvements in visceral fat (the primary driver of insulin resistance in Indians) accelerate over 3–6 months as significant weight loss occurs.
